Showing 14 posts of 14 posts found.


Brain imaging biomarker could predict how psychiatric disorder patients respond to treatment

October 21, 2020
Research and Development MDMA, PTSD

A recent study has indicated that a newly identified brain imaging biomarker could help match patients with psychiatric disorders with …


First clinical trial for MDMA and LSD combination set to go ahead

August 28, 2020
Medical Communications LSD, MDMA, PTSD

Researchers are set to investigate a combined dose of LSD and MDMA to treat patients undergoing psychotherapy. The Phase 1 …


Study finds that MDMA has long-term benefits for treating PTSD

June 11, 2020
Business Services MDMA, PTSD

PTSD patients being treated with MDMA experience numerous beneficial effects that hold strong for well after a year after completing …

New study casts doubt on effectiveness of psychotherapy treatments for military-related PTSD

February 4, 2020
Manufacturing and Production PTSD, PTSD Iraq, PTSD Therapy, PTSD WAR, PTSD military

A recent review of clinical trials shows that first-line psychotherapies are limited in how effectively they treat veterans with PTSD.


FDA puts MDMA therapy for PTSD on its Expanded Access program

January 24, 2020
Medical Communications Expanded Access, MAPS, MDMA, PTSD, pharmaceuticals, psychedelics, war

The FDA has made MDMA treatment for PTSD more accessible by putting it on the Expanded Access program. 10 sites …


Patients to recieve MDMA-assisted psychotherapy on ‘compassionate’ grounds in Israel

February 28, 2019
Research and Development MDMA, PTSD, drugs, mental health, psychedelics

The Israeli Health Ministry has approved the compassionate use of MDMA-assisted psychotherapy for 50 patients with post-traumatic stress disorder (PTSD). …


76% of patients no longer experience PTSD a year after MDMA-assisted psychotherapy

November 6, 2018
Manufacturing and Production, Research and Development MDMA, PTSD, mental health, psychotherapy, research

Promising phase II results suggest that MDMA-assisted psychotherapy may be an “innovative, efficacious treatment for posttraumatic stress disorder,” according to …


Tonix plunges 68% after PTSD drug failure

July 30, 2018
Research and Development, Sales and Marketing PTSD, Tonmya, pharma, tonix

Tonix Pharmaceuticals has announced that it has terminated its Phase 3 study of Tonmya (cyclobenzaprine HCl sublingual tablets) in military-related …


Recreational drug MDMA proves efficacy in reducing PTSD symptoms, new study finds

May 3, 2018
Research and Development MDMA, PTSD, pharma

Promising new findings have been revealed in the efficacy of MDMA in treating post-traumatic stress disorder (PTSD).


FDA fast-tracks recreational drug MDMA for treatment of PTSD

August 30, 2017
Research and Development, Sales and Marketing FDA, MDMA, PTSD, life sciences, pharma, pharmaceuticals

In another leap forward for the promising treatment, the FDA has announced that it has granted Breakthrough Therapy Designation to …

Common antibiotic shows promise as novel PTSD treatment

April 5, 2017
Research and Development PTSD, UCL, antibiotic, doxycycline

Research coming out of University College London (UCL) and the University of Zurich has indicated that common antibiotic doxycycline could …


MDMA trials get FDA backing for PTSD treatment

November 30, 2016
Research and Development FDA, MDMA, PTSD

The FDA have given the go-ahead to Phase 3 clinical trials investigating the efficacy of MDMA (Methylenedioxymethamphetamine) for treating post-traumatic …


Tonix tanks after Phase III failure

September 7, 2016
Research and Development PTSD, fibromylagia, phase III failure, tonix, tonix pharmaceuticals

New York-based Tonix Pharmaceuticals has suffered an almost 60% fall in their share price, after the announcement that its fibromyalgia …

Blog footer

Digital Pharma – Online patient recruitment drive for GSK’s anxiety drug

January 26, 2010
Research and Development GlaxoSmithKline, PTSD, digital research, orvepitant, patient recruitment

GlaxoSmithKline is readying to move its post-traumatics stress disorder candidate orvepitant into phase II trials, a move being supported by …

Latest content